GLP-1 Manufacturer Savings Programs: Wegovy, Zepbound, Ozempic, and Mounjaro Cost Guide

Why GLP-1 List Prices Are Almost Never What You Pay

GLP-1 receptor agonists carry some of the highest list prices in outpatient medicine, but the sticker price at the pharmacy counter rarely reflects what a patient with commercial insurance actually pays. Novo Nordisk and Eli Lilly both operate savings card programs that peg copays well below the list price for qualifying patients. The programs exist because payers negotiate rebates directly with manufacturers, and the savings cards let manufacturers capture brand loyalty by reducing the patient-facing cost separately.

List prices in 2025 break down as follows. Wegovy (semaglutide 2.4 mg, Novo Nordisk) carries a wholesale acquisition cost of approximately $1,349 per 28-day supply. Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg, Novo Nordisk) runs about $980 per month. Zepbound (tirzepatide, Eli Lilly) sits near $1,060 per month, and Mounjaro (tirzepatide, Eli Lilly) is priced around $1,112 per month. These figures fluctuate with pharmacy markup and dispensing fees; the numbers here reflect published wholesale acquisition cost data as of mid-2025.

The clinical argument for these drugs is strong. STEP-1 (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo (P<0.001). [1] SURMOUNT-1 (N=2,539) showed tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% with placebo (P<0.001). [2] These are large, durable effects. Patients and clinicians want access. Cost is the primary barrier, and manufacturer programs are the first line of attack on that barrier.

Novo Nordisk Savings Programs: Wegovy and Ozempic

Novo Nordisk runs separate savings card programs for Wegovy and Ozempic, and the eligibility rules are different enough to matter.

Wegovy Savings Card. Commercially insured patients who are prescribed Wegovy for chronic weight management may pay as little as $0 per month for up to 13 fills. The program is managed through Novo Nordisk's "My$99Insulin" parallel infrastructure and branded separately as the Wegovy Savings Card at wegovysavings.com. Income is not tested. The single hard requirement: the patient must have commercial (private) insurance that covers Wegovy. Patients on Medicare Part D, Medicaid, or any other federal or state program are explicitly excluded. After the initial 13-fill benefit period, the copay cap rises; patients should re-verify terms annually because Novo Nordisk adjusts copay caps each calendar year. [3]

Uninsured patients face a different calculation. Novo Nordisk offers a separate "NovoCare" patient assistance program for uninsured or underinsured individuals who meet income thresholds (generally at or below 400% of the federal poverty level). Application is done through the NovoCare portal and requires income documentation.

Ozempic Savings Card. The Ozempic savings card caps monthly out-of-pocket cost at $25 for up to 24 months for eligible commercially insured patients. The drug must be prescribed for its FDA-approved indication (type 2 diabetes mellitus), and patients on government insurance programs are again excluded. For patients whose insurance does not cover Ozempic, the card may still reduce cost to $99 per month in some pharmacy networks, though that tier is subject to change.

The SELECT cardiovascular outcomes trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% (HR 0.80 to 95% CI 0.72, 0.90) in adults with overweight or obesity and established cardiovascular disease. [4] That cardiovascular data has expanded insurer coverage of Wegovy for patients with qualifying cardiac history, which in turn makes more patients eligible for the $0 savings card tier.

Eli Lilly Savings Programs: Zepbound and Mounjaro

Eli Lilly operates parallel savings programs for its two tirzepatide brands, with the same underlying active ingredient but different approved indications.

Zepbound Savings Card. Commercially insured patients prescribed Zepbound (approved for chronic weight management, BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity) [5] may pay as little as $25 per month. Lilly's program caps savings at $150 per fill, which at the current Zepbound list price means patients whose insurance covers Zepbound substantially pay the $25 copay. Patients without insurance who do not qualify for assistance programs paid approximately $349 to $499 per month through Lilly's "Lilly Direct" self-pay vials program introduced in 2024. That program ships direct-to-patient at reduced cost and bypasses the traditional pharmacy channel.

Mounjaro Savings Card. The Mounjaro savings card mirrors the structure: commercially insured patients prescribed Mounjaro for type 2 diabetes pay as low as $25 per month. The maximum savings per fill under the current program is $573. Patients using Mounjaro off-label for weight loss face the same eligibility rules; the card applies regardless of the prescribing rationale as long as commercial insurance is active.

SURMOUNT-2 (N=938, adults with T2D and obesity) showed tirzepatide 15 mg reduced body weight by 14.7% at 72 weeks versus 3.2% with placebo (P<0.001), with simultaneous HbA1c reductions of 2.58 percentage points. [6] That dual-indication profile means prescribers sometimes choose between Mounjaro (diabetes) and Zepbound (obesity) for the same patient, which has direct implications for which savings card applies.

What "Commercial Insurance" Actually Means for Savings Eligibility

The phrase "commercial insurance" is the single biggest source of confusion around manufacturer savings cards.

Commercial insurance means employer-sponsored plans, marketplace (ACA exchange) plans, and individual private plans. It does not include Medicare (Parts A, B, C, or D), Medicaid, TRICARE, VA benefits, or any plan funded in full or in part by a federal or state government. A patient who has both commercial insurance through an employer and Medicaid secondary coverage is typically ineligible for manufacturer cards because the presence of any government coverage disqualifies enrollment under federal anti-kickback statute safe harbors.

Part D coverage is the most common disqualifier. Adults 65 and older are almost universally on Medicare Part D for prescription drug coverage and therefore cannot use manufacturer cards for any GLP-1 regardless of what they pay out of pocket. This is not a drug-specific rule; it applies across all manufacturer co-pay cards.

The AACE 2016 clinical practice guidelines on obesity state: "Cost and insurance coverage are major barriers to the initiation and continuation of pharmacotherapy for obesity." [7] That observation is as accurate today as it was nine years ago. Manufacturer savings programs partially address this barrier for commercially insured patients, but leave a significant gap for the Medicare population.

Step-by-Step: How to Enroll in a Manufacturer Savings Card

The enrollment process is similar for all four drugs.

1. Confirm that your insurance plan covers the drug (prior authorization may be required). Call the benefits line on your insurance card or use the insurer's online formulary tool.
2. Visit the manufacturer's official savings portal. For Wegovy and Ozempic, that is novonordisk.com or the drug-specific savings page. For Zepbound and Mounjaro, visit lilly.com and manage to the savings card page for each product.
3. Complete the enrollment form. You will need your insurance ID, group number, date of birth, and prescriber NPI. No income documentation is required for commercial-insurance tiers.
4. Print, email, or load the digital card to your phone. Present it at the pharmacy along with your insurance card. The pharmacy runs the manufacturer card as a secondary claim after the primary insurance adjudicates.
5. Re-enroll each January. Programs reset on a calendar-year basis and terms change. Patients who auto-renew without checking may find the copay cap has shifted.

Patients who are denied savings cards due to Medicare or Medicaid coverage should ask their prescriber about (a) the NovoCare or LillyAnswers patient-assistance programs, which provide medication at no cost to qualifying low-income patients, and (b) state pharmaceutical assistance programs, which vary by state.

When Insurance Doesn't Cover GLP-1s: Out-of-Pocket Alternatives

Roughly 25% of commercial insurance plans still exclude Wegovy and Zepbound from formulary as of early 2025, according to benefit-administrator surveys. When insurance denies coverage entirely, the savings card does not help.

Goodrx and third-party coupons. GoodRx pricing for Wegovy hovers around $1,100 to $1,300 per month depending on pharmacy, which is below list price but still inaccessible for most patients without meaningful income. Ozempic GoodRx pricing runs approximately $850 to $950 per month.

Lilly Direct self-pay vials. Eli Lilly launched a direct-to-patient program in 2024 offering Zepbound single-dose vials at $399 to $549 per month (doses 2.5 mg to 5 mg at the lower end, higher doses at the upper end). These vials require a valid prescription but bypass insurance entirely. The FDA confirmed these vials use the same tirzepatide formulation as the autoinjector pen. Patients must draw and inject from a vial rather than using the pre-filled pen.

Compounded semaglutide and tirzepatide. During the FDA shortage period, 503B outsourcing facilities compounded semaglutide and tirzepatide at substantially lower cost, sometimes $150 to $350 per month. The FDA removed tirzepatide from the drug shortage list in December 2024 and semaglutide in early 2025, which means compounded versions from 503A and 503B pharmacies are no longer permitted under the shortage exemption. Patients receiving compounded GLP-1s should verify their pharmacy's current regulatory standing directly with the FDA's drug shortage database. [8]

The HealthRX clinical team uses the following four-question access screen before routing patients to a savings program:

1. Does the patient have commercial insurance (non-government)?
2. Is the target drug on the formulary (even with prior authorization)?
3. Has the prescriber documented the FDA-approved indication (obesity with qualifying BMI, or type 2 diabetes)?
4. Has the patient previously enrolled in this calendar year's program (some cards allow only one enrollment per 12-month period)?

A "yes" to all four routes the patient to the manufacturer card. A "no" on question 1 routes to patient-assistance programs. A "no" on question 2 triggers a formulary exception request or switches to the alternative brand.

Prior Authorization: The Step Before the Savings Card

Manufacturer savings cards are irrelevant if the pharmacy claim never adjudicates in the first place. Most commercial plans require prior authorization (PA) for Wegovy and Zepbound, and many require it for Ozempic and Mounjaro as well.

PA criteria for weight-management indications (Wegovy, Zepbound) typically require documentation of BMI ≥30 kg/m² or BMI ≥27 kg/m² with an obesity-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea), plus evidence that the patient has attempted a supervised diet or behavioral program. The FDA label for Wegovy specifies adjunct use "to a reduced-calorie diet and increased physical activity." [3] The FDA label for Zepbound carries the same language. [5]

PA for diabetes indications (Ozempic, Mounjaro) typically requires documentation of a type 2 diabetes diagnosis and, at many plans, failure of at least one first-line agent (metformin). Step therapy policies vary widely by payer.

Denials are common. A 2023 analysis published in JAMA found prior authorization denials for anti-obesity medications were upheld on appeal less than 30% of the time, suggesting many initial denials can be reversed with adequate clinical documentation. Patients should request a peer-to-peer review between their prescriber and the insurance medical director when a PA denial is received.

Comparing All Four Programs Side by Side

| Drug | Active Ingredient | Indication | List Price/Month | Savings Card Min Copay | Uninsured Option | |------|------------------|------------|-----------------|----------------------|-----------------| | Wegovy | Semaglutide 2.4 mg | Chronic weight management | ~$1,349 | $0 (up to 13 fills) | NovoCare PAP | | Ozempic | Semaglutide 0.5 to 2 mg | Type 2 diabetes | ~$980 | $25/month (up to 24 months) | NovoCare PAP | | Zepbound | Tirzepatide 2.5 to 15 mg | Chronic weight management | ~$1,060 | $25/month | Lilly Direct vials ($399, $549) | | Mounjaro | Tirzepatide 2.5 to 15 mg | Type 2 diabetes | ~$1,112 | $25/month | LillyAnswers PAP |

Note: Copay amounts and program terms are subject to change. Verify current terms at the manufacturer's official site before dispensing.

Long-Term Cost and Clinical Duration

Patients initiating GLP-1 therapy should anticipate indefinite treatment. STEP-5 (N=304 to 104 weeks) demonstrated that the weight loss achieved with semaglutide 2.4 mg was maintained only with continued treatment; patients who completed the 104-week active-treatment period maintained a 15.2% weight reduction. [9] SURMOUNT-4 (N=783) showed that patients who withdrew tirzepatide after 36 weeks of treatment regained approximately two-thirds of their lost weight by week 88, compared with continued weight reduction in the maintenance group (P<0.001). [10]

These data confirm that GLP-1 therapy is not a finite course. Patients and prescribers should plan for ongoing cost management from the outset. Savings card programs that expire after 13 or 24 months represent a temporary subsidy, not a permanent solution. Advocacy for insurance formulary inclusion is the more durable path.

The American Association of Clinical Endocrinology 2022 consensus noted: "Obesity is a chronic disease requiring long-term treatment; short-term coverage policies are inconsistent with evidence-based management." [7] That position aligns with the clinical trial data and has been used successfully by prescribers in appeals to insurers.

What the Medicare Drug Price Negotiation Means for 2026

The Inflation Reduction Act authorized CMS to negotiate prices directly for select high-expenditure Medicare Part D drugs. Semaglutide products are candidates for negotiation in future cycles. The first negotiated prices under the IRA took effect January 1, 2026, for the initial 10 drugs named. GLP-1s were not in the first negotiation cycle, but the program is expected to expand. If semaglutide enters negotiation, the resulting CMS Maximum Fair Price would lower what Medicare Part D plans pay, which could eventually reduce Part D cost-sharing for Medicare beneficiaries who currently have no access to manufacturer savings cards.

No firm negotiated price for GLP-1s has been published as of this article's review date. Patients on Medicare should monitor CMS announcements at cms.gov and the drug negotiation page at cms.gov/inflation-reduction-act.

Special Populations: Pregnancy, Adolescents, and BMI Thresholds

Pregnancy. Both Wegovy and Zepbound carry FDA Pregnancy Category warnings recommending discontinuation at least 2 months before a planned pregnancy due to the drug's long half-life and animal teratogenicity data. Neither manufacturer savings program addresses gestational use, and prescribing during pregnancy is not an approved indication. [3,5]

Adolescents. The FDA approved Wegovy for adolescents aged 12 and older in December 2022. The Wegovy savings card extends to this age group provided commercial insurance is active. STEP TEENS (N=201) showed semaglutide 2.4 mg reduced BMI by 16.1% at 68 weeks versus a 0.6% increase with placebo. [11]

BMI thresholds. Wegovy is approved for adults with BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity. Zepbound carries identical BMI criteria. [5] Insurance plans that use BMI <30 as a blanket exclusion are applying criteria inconsistent with the FDA label for patients with comorbidities; this is a viable basis for PA appeal.